Predictors of Metastasis in 68GA-Prostate Specific Membrane Antigen Pet-CT in the Primary Staging of Prostate Cancer

Erkin Karaca,Erdem Kisa,Mehmet Caglar Cakici,Taha Cetin,Mehmet Yigit Yalcin,Mert Hamza Ozbilen,Cagdas Bildirici,Gokhan Koc

DOI: https://doi.org/10.3390/jcm13102774

IF: 3.9

2024-05-09

Journal of Clinical Medicine

Abstract:Background: The objective of this study was to investigate factors influencing Gallium 68 Prostate Specific Membrane Antigen Positron Emission Tomography (Ga68 PSMA PET-CT) uptake for primary staging in prostate cancer. Methods: Retrospective analysis was conducted on 499 non-metastatic and 243 de novo metastatic prostate cancer cases undergoing Ga68 PSMA PET-CT. Demographic, clinical, and imaging data were collected and analyzed. Multivariate logistic regression determined independent risk factors for metastasis detection on Ga68 PSMA PET-CT. Results: Metastatic cases showed higher levels of total PSA, PSA density (dPSA) and biopsy ISUP grade group compared to non-metastatic cases. Multivariate analysis identified cT2 stage and dPSA as independent predictors of metastasis detection on Ga68 PSMA PET-CT. Conclusions: Ga68 PSMA PET-CT plays a crucial role in prostate cancer staging, with identified factors such as clinical T stage and dPSA significantly impacting its diagnostic accuracy. These findings underscore the importance of Ga68 PSMA PET-CT in refining clinical staging and guiding treatment decisions for prostate cancer patients.

medicine, general & internal

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the factors that affect the uptake of 68Ga - prostate - specific membrane antigen positron - emission tomography (Ga68 PSMA PET - CT) in the initial staging of prostate cancer. Specifically, the study aims to identify which clinical and biochemical features can be used as independent risk factors for predicting metastasis detected by Ga68 PSMA PET - CT in prostate cancer patients during the initial staging. ### Research Background Prostate cancer is one of the most common cancers among men worldwide and is also the sixth leading cause of cancer - related deaths in men. Traditional methods for diagnosing prostate cancer include prostate - specific antigen (PSA) level detection, digital rectal examination, and staging based on the tumor, node, metastasis (TNM) classification system. However, these traditional methods have limitations in detecting micrometastases and lymph node involvement. In recent years, the application of new technologies such as multi - parameter prostate magnetic resonance imaging (MpMRI) has significantly improved the diagnostic accuracy and reduced the risks of over - diagnosis and over - treatment. ### Research Objectives In order to improve the diagnostic accuracy of prostate cancer and optimize treatment strategies, this study aims to deeply explore various factors that affect Ga68 PSMA PET - CT uptake. Through a comprehensive analysis of these factors and their impact on imaging results, the study hopes to provide a basis for optimizing imaging protocols, thereby providing more accurate guidance for the clinical staging and treatment decision - making of prostate cancer patients. ### Main Findings - **Statistical Analysis**: Through a retrospective analysis of 499 non - metastatic and 243 newly - diagnosed metastatic prostate cancer patients, the study found that the total PSA level, PSA density (dPSA), and biopsy ISUP grade group (GG) in metastatic cases were significantly higher than those in non - metastatic cases. - **Multivariate Logistic Regression Analysis**: cT2 stage and dPSA were identified as independent predictors of metastasis detected by Ga68 PSMA PET - CT. ### Conclusions Ga68 PSMA PET - CT plays a crucial role in the staging of prostate cancer, and factors such as the clinical T stage and dPSA have a significant impact on its diagnostic accuracy. These findings emphasize the importance of Ga68 PSMA PET - CT in optimizing the clinical staging of prostate cancer and guiding treatment decision - making. Through this study, the authors hope to provide more scientific basis for the precise diagnosis and personalized treatment of prostate cancer, thereby improving the prognosis and quality of life of patients.

Predictors of Metastasis in 68GA-Prostate Specific Membrane Antigen Pet-CT in the Primary Staging of Prostate Cancer

Predictive significance of intraprostatic volumetric parameters derived from early and standard time 68Ga-PSMA PET/CT images in newly diagnosed prostate cancer patients

Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging

The role of [68Ga]Ga-PSMA PET/CT in primary staging of newly diagnosed prostate cancer: predictive value of PET-derived parameters for risk stratification through machine learning

68 Ga-PSMA-617 PET/CT: a Promising New Technique for Predicting Risk Stratification and Metastatic Risk of Prostate Cancer Patients

Predictive value of volumetric parameters based on 18F-PSMA-1007 PET/CT for prostate cancer metastasis

Head‐to‐head comparison of GA‐68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer

Predictors of PSMA positivity at initial staging of prostate cancer.

18F-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer

Enhancing Prostate Cancer Staging: Association of 68Ga-PSMA PET/CT Imaging with Histopathological Grading in Treatment-Naive Patients

18F-PSMA-1007 PET/CT in Primary Prostate Cancer: Using Tpsa to Detect Distant Metastasis and Incorporating SUVmax to Characterize Primary Prostate Cancer and Distant Metastasis

[68Ga-Psma-i&t PET/CT for Assessment of Tumor Burden in Primary Lesions of Treatmentnaïve Prostate Cancer].

The 18F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer

The Relationship between D'Amico and ISUP Risk Classifications and 68Ga-PSMA PET/CT SUVmax Values in Newly Diagnosed Prostate Cancers

[68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer

F-18-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer

Comparison of Ga-68 PSMA PET/CT and Multiparametric MRI for Initial Detection and Staging of Prostate Cancer

The role of Ga68 PSMA PET/CT imaging in Lu177 PSMA treatment planning in metastatic castration-resistant prostate cancer

The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer

Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy

A Single-Center, Multi-Factor, Retrospective Study to Improve the Diagnostic Accuracy of Primary Prostate Cancer Using [68Ga]ga-Psma-11 Total-Body PET/CT Imaging.